Navigation Links
Adeona's Alzheimer's Disease Pivotal Clinical Study Results Abstract Accepted for Presentation at the American Academy of Neurology's 63rd Annual Meeting
Date:2/8/2011

roduct's zinc origin, one of the two major constituents of the proprietary, gastro-retentive, sustained-release tablet. The new branding for reaZin will be unveiled at the Company's Investor Day on Zinc Deficiency in Alzheimer's Disease, taking place this afternoon in Ann Arbor, MI.

"The large gathering of neurologists at the American Academy of Neurology's 63rd Annual Meeting is an excellent scientific venue to present the pivotal clinical study results of our zinc and cysteine-based prescription medical food product candidate for Alzheimer's disease and mild cognitive impairment," stated James S. Kuo, M.D., M.B.A., Adeona's Chairman and CEO. "We are delighted that our clinical investigator has been accepted to present this important clinical data."

About the American Academy of Neurology

The American Academy of Neurology, an association of more than 22,500 neurologists and neuroscience professionals, is dedicated to promoting the highest quality patient-centered neurologic care. A neurologist is a doctor with specialized training in diagnosing, treating and managing disorders of the brain and nervous system such as stroke, Alzheimer's disease, epilepsy, Parkinson's disease, and multiple sclerosis. For more information about the American Academy of Neurology, visit http://www.aan.com. For more information about the American Academy of Neurology's 63rd Annual Meeting set for April 9 - 16, 2011, at the Hawaii Convention Center, visit http://www.aan.com/go/am.

About the Pivotal Clinical Study Evaluating reaZin

reaZin (zinc cysteine), formerly named Zinthionein, is a proprietary oral tablet formulation of zinc and cysteine, an amino acid with potent anti-oxidant properties. Adeona is developing this product candidate for the dietary management of Alzheimer's disease and mild cognitive impairment as a prescri
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
4. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
5. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
6. Baxter and The Alzheimers Disease Cooperative Study Group to Pursue a Phase III Study of Gammagard Liquid in Patients With Alzheimers Disease
7. Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease
8. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
9. Public Forum to Discuss Addiction as a Treatable Disease and Highlight National Alcohol and Drug Addiction Recovery Month
10. K-State Researchers Bringing Expertise to Kansas City Symposium on Disease and National Security
11. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... N.J. , July 22, 2014  Vernalis plc ... achievement of proof-of-concept (POC) for CCP-08, the third ... prescription cough cold collaboration. Under this collaboration, POC ... a successful human pilot comparative study against an ... achieving POC, Vernalis will make a milestone payment ...
(Date:7/22/2014)... 2014 Quantum Materials Corporation (OTCQB:QTMM) (QMC) announced today the addition ... to the Board of Directors. QMC also announced formation of ... QMC Chief Science Officer and Board of Directors Member, along with ... University and Mr. Tomio Gotoh , a pioneer of the ... " Quantum Materials welcomes two new outside Board members, Mr. ...
(Date:7/22/2014)... July 22, 2014 ... company focused on solid dose formulations of therapeutics ... formulation of octreotide acetate achieved successful results in ... currently marketed liquid product (Sandostatin®).  Based on these ... production process to a contract manufacturing organisation (CMO), ...
Breaking Medicine Technology:Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 2Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 2Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 3Quantum Materials Announces New Outside Directors and Adds Scientific Advisory Board 4Glide Pharma Completes Successful Proof-of-Concept Study with Novel Solid Dose Formulation of Octreotide 2
... 24, 2012  Covance Inc. (NYSE: CVD ) today ... Health Care Conference on Tuesday, February  28, 2012 at 9:00 ... at www.covance.com . In order to register and download any ... Covance, with headquarters in Princeton, New Jersey, is one of ...
... products in the pipeline and more at the edge ... life of mature brands are critical to today,s pharmaceutical ... many as 10 years and billions of dollars to ... To help biopharmaceutical companies more effectively conduct ...
Cached Medicine Technology:Covance to Present at Citi 2012 Global Health Care Conference 2Report Delivers ROI Analysis on Key Lifecycle Management Strategies Utilized by the Pharmaceutical Industry 2
(Date:7/23/2014)... 23, 2014 PartnerTech Inc. , ... Lawrenceville, Georgia, welcomed Andreas von Uexkull to their facilities, ... the U.S. von Uexkull, a top trade official from ... of the U.S. to bring awareness and insight to ... Investment Partnership (TTIP). , As an expert on ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Previously, the crew ... pencil and a spreadsheet. Now, the department’s 53 ... Scheduling and Workforce Management system. , “Scheduling our personnel with ... It was hard to keep track of when people could ... this time to this time, and we would have to ...
(Date:7/23/2014)... Controlling pain during childbirth and post delivery may reduce ... a Northwestern Medicine perinatal psychiatrist, in a July 23 ... Wisner,s editorial is based on a new Chinese study ... anesthesia during a vaginal delivery had a much lower ... the epidural. , "Maximizing pain control in labor and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Print ... Print Audit Facilities Manager web portal. Facilities Manager ... releases of the software as well as numerous ... , Print Audit Facilities Manager is a powerful, ... to remotely collect meter reads, automate supplies fulfillment ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... of white party dresses to its product category. ... now available on its website. As a special offer, all ... can get a discounted rate, up to 54% off. , ... customers, so its marketing specialist believes the new white party ...
Breaking Medicine News(10 mins):Health News:Swedish Official Tours PartnerTech’s U.S. Facility 2Health News:Swedish Official Tours PartnerTech’s U.S. Facility 3Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 2Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 3Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: